A phase I clinical trial also revealed that the combination of FAK inhibitor defactinib and RAF/MEK inhibitor VS-6766 achieved promising results in low-grade serous ovarian cancer (62). The gene discussed is MAP2K7; the disease is ovarian serous adenocarcinoma.